Fibrotic Changes Depicted by Thin-Section CT in Patients With COVID-19 at the Early Recovery Stage: Preliminary Experience

Zhen Lu Yang†, Chong Chen†, Lu Huang, Shu Chang Zhou, Yu Na Hu, Li Ming Xia and Yan Li*

Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Objectives: To analyze follow-up CTs of patients recovering from COVID-19 in Wuhan, focusing on fibrotic change and its relevant risk factors.

Methods: From January 13 to February 27, 2020, 166 hospitalized patients meeting our criteria were included. The scores of fibrotic patterns on follow-up CT were evaluated. Patients were designated as group 1 (with CT evidence of fibrotic pattern) and group 2 (without CT evidence of fibrotic pattern). Multivariate logistic regression was performed to explore risk factors for fibrotic change in patients with COVID-19.

Results: The follow-up CTs were obtained on 56 days (median, IQR 51–63 days) after symptom onset. Of the 166 patients (mean age, 57 ± 15 years; 69/166 male), 46% (76/166) had CT evidence of fibrotic change and 77% (127/166) were severe or critical cases. Among patients with fibrotic change on CT, 84% (64/76) got a minimal or mild score of fibrosis. The high total score on peak CT, peak eosinophils, erythrocyte sedimentation rate (ESR) and advancing age were related to lung fibrotic change in patients with COVID-19.

Conclusion: Forty six percentages of patients (mainly severe or critical cases) with COVID-19 showed fibrotic change on follow-up CT at early recovery phase, while the extent of fibrosis was not large. The advancing age, high total score on peak CT, peak eosinophils and ESR were associated with fibrotic change depicted by CT in patients recovering from COVID-19. An extended follow up by CT imaging and pulmonary function testing is necessary to fully assess the sequela of COVID-19.

Keywords: coronavirus disease 2019 (COVID-19), fibrotic change, chest CT imaging, follow-up, risk factors

HIGHLIGHTS
- In our cohort, 77% (127/166) patients were severe or critical cases and 46% (76/166) patients with COVID-19 presented with fibrotic patterns on follow-up CT at early recovery phase (56 days after symptom onsets).
- The scores of fibrotic changes in 84% (64/76) patients were estimated as minimal or mild.
- The high total score on peak CT, peak eosinophils, erythrocyte sedimentation rate (ESR) and advancing age were related to lung fibrotic change depicted by CT in patients with COVID-19.
INTRODUCTION

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in December 2019 and rapidly reached a global pandemic (1, 2). COVID-19 is highly infectious and has a high mortality rate in elderly patients or those with comorbidities (3, 4). By September 11, 2020, there are more than 27 million confirmed cases and 899,916 deaths globally according to reports of World Health Organization (WHO) (5).

Since the outbreak of COVID-19, many studies have been conducted to reveal the epidemiological features, symptoms/signs, laboratory data, radiographic findings and treatments of this disease to facilitate the diagnosis and management of patients (6–11). Chest CT is critical in early diagnosis, dynamic observation, treatment evaluation and prognostic prediction (12, 13), and its patterns have been well-described in the acute and early recovery phases (2, 7, 8, 14, 15).

Previous literatures reported that 62% of patients with Severe Acute Respiratory Syndrome (SARS) and 33% patients with Middle East Respiratory Syndrome (MERS) showed evidences of lung fibrosis after recovery (16, 17). Those suggested that fibrotic changes may develop as a crucial complication in patients with COVID-19 (18). However, follow-up information and evidence of lung fibrosis in patients recovering from COVID-19 is rare at present. Wuhan city of China is the early pandemic center of COVID-19 and has accumulated huge recovery cases as well as corresponding imaging data. Therefore, the purpose of this study is to report the follow-up CT findings of patients recovering from COVID-19 in Wuhan, with focus on the lung fibrotic patterns and its relevant risk factors; this may make sense for understanding disease course and better managing infected patients.

MATERIALS AND METHODS

Patients and Data Collection

This retrospective study was approved by our institutional review board (IRB number of TJ-C20200141) with a waived informed consent of patients. From January 13 to February 27, 2020, a total of 575 patients (mean age, 60 ± 14 years; 46% [267/575] male) with confirmed COVID-19 according to diagnostic criteria of WHO (19) were hospitalized in our hospital and had at least two chest CT exams during the study period. Patients were included when meeting one of the following inclusion criteria:
TABLE 1 | CT scoring system of lesion extent on peak CT and fibrosis extent on last follow-up CT.

| Lesion extent or fibrosis extent of a lobe | CT score of a lobe |
|------------------------------------------|-------------------|
| 0                                        | 0                 |
| 1–5%                                     | 1                 |
| 6–24%                                    | 2                 |
| 25–49%                                   | 3                 |
| 50–74%                                   | 4                 |
| 75–100%                                  | 5                 |

(Figure 1): (a) The interval from symptom onset to last follow-up CT was more than 50 days in most patients, whether lesions were absorbed or not. (b) Lung lesions on last follow-up CT were completely absorbed within 50 days after symptom onset. The exclusion criteria were (Figure 1): (a) Lesions were not resolved on last follow-up CT; (b) Postpartum (n = 1); (c) With cancer (n = 1); (d) Death during hospitalization (n = 6); (e) Undergoing lung surgery (n = 4) because of potential inflammation or hemorrhage. As a result, 166 patients were included in this study.

All of the 166 patients were discharged at the beginning of this study. The discharge criteria were provided by National Health Commission of China (20): (a) No fever for more than 3 days; (b) Significantly alleviated respiratory symptoms; (c) Radiographic abnormalities on chest radiograph or CT were improved; (d) Two consecutive nucleic acid tests with respiratory samples were negative for SARS-CoV-2 with an interval of at least 24 h.

We recorded all available clinical, laboratory and treatment information of patients extracted from clinical electronic medical records and nursing records in our hospital information system (HIS).

Chest CT Imaging Protocols and Interpretation

The CT systems and imaging parameters used in this work were described in our previous study (21). All images were obtained on one of the three CT systems (Siemens Healthineers, Germany Optima 660, GE, America; uCT 780, United Imaging, China; Somatom Definition AS+) with patients in supine position. The main scanning parameters were as follows: tube voltage = 120 kVp, automatic tube current modulation (30–70 mAs), slice thickness = 0.625–1.250 mm, field of view = 350 mm.

For each one patient, a total of two scans needed to be evaluated (peak chest CT and last follow-up chest CT). Two radiologists (with 8 and 3 years of experience in interpreting chest CT imaging, respectively) reviewed all images by consensus. The chest CT scan with the most severe changes, which was defined as peak chest CT, was determined by comparing series of CT scans of one patient.

For peak chest CT, we assessed radiologic abnormalities, including ground-glass opacity (GGO), consolidation, reticulation/thickened interlobular septa, lung distortion and nodular. The severity of each lung lobe (left upper/lower lobe, right upper/middle/lower lobe) was scored on a basis of lesion extent in the corresponding lobe, as 0 (0%), 1 (1–5%), 2 (6–24%), 3 (25–49%), 4 (50–74%), and 5 (75–100%) (Table 1). Total score of five lobes of each patient was summed when 0 as none, 1–5 as minimal, 6–10 as mild, 11–15 as moderate, 16–20 as severe, 21–25 as critical.

As to last follow-up chest CT images, we evaluated the evidence of fibrotic changes, including parenchymal bands, traction bronchiectasis, irregular interfaces, lung distortion, and honeycombing (16, 22–24). Lung distortion was defined as anatomical displacement of bronchus, vessel and interlobular

TABLE 2 | Characteristics and treatments of patients with COVID-19.

| Age (years) | Total patients (n = 166) | With CT evidence of fibrosis (group 1, n = 76) | Without CT evidence of fibrosis (group 2, n = 90) | P-value |
|-------------|-------------------------|-----------------------------------------------|-------------------------------------------------|---------|
| Mean (Range) | 57 ± 15 (14–89)         | 63 ± 11 (28–86)                              | 52 ± 16 (14–89)                                 | < 0.001 |
| Male sex    | 69 (42%)                | 37 (49%)                                     | 32 (36%)                                       | 0.087   |
| Time interval (median, days) | | | | |
| From onset of symptom to peak CT | 20 (12–26) | 23 (16–25) | 18 (11–24) | 0.001 |
| From onset of symptom to follow-up CT | 56 (51–63) | 58 (54–66) | 54 (35–59) | < 0.001 |
| Severity of illness | Moderate | Severe | Critical | |
| Mean age | | | | |
| Oxygen support | 145/166 (87%) | 72/76 (95%) | 73/90 (81%) | 0.009 |
| Nasal cannula or face mask | 137/166 (83%) | 64/76 (84%) | 73/90 (81%) | 0.600 |
| Noninvasive mechanical ventilation | 7/166 (4%) | 7/76 (9%) | 0/90 (0%) | 0.011 |
| Invasive mechanical ventilation | 1/166 (1%) | 1/76 (1%) | 0/90 (0%) | 0.458 |
| Glucocorticoids (methylprednisolone) | 75/166 (45%) | 50/76 (66%) | 25/90 (28%) | < 0.001 |
| Immunglobulin | 57/166 (34%) | 35/76 (46%) | 22/90 (24%) | 0.003 |
| Antiviral agents | 159/166 (96%) | 75/76 (99%) | 84/90 (93%) | 0.186 |
| Antibiotics | 110/166 (66%) | 63/76 (83%) | 47/90 (52%) | < 0.001 |
| Antifungal agents | 2/166 (1%) | 2/76 (3%) | 0/90 (0%) | 0.208 |
| ECMO | 0/166 (0%) | 0/76 (0%) | 0/90 (0%) | 1.000 |
| CRRT | 0/166 (0%) | 0/76 (0%) | 0/90 (0%) | 1.000 |

Data are n (%) or median (IQR). Mean age is mean ± standard deviation. COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy.
TABLE 3 | Peak laboratory data of patients with COVID-19.

| White blood cells | Normal range | Total patients (n = 166) | With CT evidence of fibrosis (group 1, n = 76) | Without CT evidence of fibrosis (group 2, n = 90) | P-value |
|-------------------|--------------|--------------------------|-----------------------------------------------|-------------------------------------------------|---------|
| Leucocytes (×10^9/L) | 3.5–9.5 | 7.25 (5.63–9.75) | 8.52 (6.45–12.49) | 6.55 (5.43–8.01) | < 0.001 |
| Increased | 45/166 (27%) | 33/76 (43%) | 12/90 (13%) | < 0.001 |
| Neutrophils (×10^9/L) | 1.8–6.3 | 4.92 (3.55–7.46) | 6.20 (4.42–10.39) | 4.05 (3.08–5.82) | < 0.001 |
| Increased | 52/166 (31%) | 36/76 (47%) | 16/90 (18%) | < 0.001 |
| Lymphocytes (×10^9/L) | 1.1–3.2 | 1.82 (1.36–2.25) | 1.73 (1.23–2.16) | 1.85 (1.44–2.28) | 0.125 |
| Increased | 4/166 (2%) | 3/76 (4%) | 1/90 (1%) | 0.497 |
| Eosinophils (×10^9/L) | 0.02–0.52 | 0.17 (0.10–0.26) | 0.21 (0.14–0.33) | 0.14 (0.09–0.23) | 0.003 |
| Increased | 11/166 (7%) | 6/76 (8%) | 5/90 (6%) | 0.546 |
| Monocytes (×10^9/L) | 0.1–0.6 | 0.64 (0.50–0.83) | 0.72 (0.57–0.93) | 0.60 (0.47–0.71) | < 0.001 |
| Increased | 93/166 (56%) | 51/76 (67%) | 42/90 (47%) | 0.008 |

**Cytokines**

| Interleukin-1β (pg/mL) | <5 | 5.00 (5.00–5.30) | 5.00 (5.00–5.30) | 5.00 (5.00–5.15) | 0.771 |
| Increased | 40/145 (28%) | 19/70 (27%) | 21/75 (28%) | 0.908 |
| Interleukin-2 receptor (U/mL) | 223–710 | 616.00 (440.00–917.00) | 777.00 (557.50–1090.50) | 511.00 (365.50–698.00) | < 0.001 |
| Increased | 56/145 (39%) | 77/70 (54%) | 77/75 (54%) | < 0.001 |
| Interleukin-6 (pg/mL) | <7.0 | 7.21 (5.11–20.38) | 10.61 (3.93–31.02) | 5.36 (2.45–13.14) | 0.030 |
| Increased | 76/145 (52%) | 45/70 (64%) | 31/75 (41%) | 0.006 |
| Interleukin-8 (pg/mL) | <62 | 13.60 (9.20–23.70) | 16.95 (9.70–25.38) | 12.30 (8.10–22.70) | 0.039 |
| Increased | 8/145 (6%) | 3/70 (4%) | 2/75 (3%) | 0.792 |
| Interleukin-10 (pg/mL) | <9.1 | 5.00 (5.00–9.15) | 5.00 (5.00–9.15) | 5.00 (5.00–9.15) | 0.034 |
| Increased | 27/145 (19%) | 18/70 (26%) | 9/75 (12%) | 0.034 |
| Tumor necrosis factor α (pg/mL) | <8.1 | 9.20 (7.50–11.90) | 10.80 (8.85–14.73) | 8.20 (6.65–9.95) | < 0.001 |
| Increased | 96/145 (66%) | 55/70 (67%) | 40/75 (53%) | 0.001 |

**Other biomarkers**

| Lactate dehydrogenase (U/L) | 135–225 | 283.00 (224.25–350.50) | 308.00 (264.75–452.25) | 250.00 (208.25–305.50) | < 0.001 |
| Increased | 126/166 (76%) | 68/76 (89%) | 58/90 (64%) | < 0.001 |
| Erythrocyte sedimentation rate (mm/H) | 0.00–15.00 | 35.00 (19.00–64.00) | 58.00 (33.50–81.00) | 22.00 (13.00–34.75) | < 0.001 |
| Increased | 89/117 (76%) | 55/58 (93%) | 34/58 (59%) | < 0.001 |
| C-reactive protein (mg/L) | <1.0 | 22.80 (4.60–72.50) | 61.70 (15.80–135.55) | 11.25 (2.47–33.62) | < 0.001 |
| Increased | 151/166 (91%) | 76/90 (84%) | 76/90 (84%) | 0.001 |

Data are median (IQR) or n/N (%), where N is the total number of patients with available data. COVID-19, coronavirus disease 2019.

The septum of lung. Traction bronchiectasis was defined as dilation of bronchus and irregularity of bronchial wall. The lesion extent of each lung lobe was scored as 0 (0%), 1 (1–5%), 2 (6–24%), 3 (25–49%), 4 (50–74%), and 5 (75–100%) (23, 24) (Table 1). Total fibrosis score of five lobes of each patient was summed with 0 as none, 1–5 as minimal, 6–10 as mild, 11–15 as moderate, 16–20 as severe, 21–25 as critical. The distribution of fibrotic patterns was recorded as: predominantly peripheral, peribronchovascular, or random. The residual GGO and consolidation on last follow-up CT were also recorded.

According to evaluation of fibrotic changes on CT, patients were classified as group 1 (with CT evidence of fibrotic pattern) and group 2 (without CT evidence of fibrotic pattern) for analysis.

### Statistical Analysis

The statistical analysis of this study was performed using Python (version 3.8.1). When P-value was ≤0.05, a significantly statistical difference was considered. Continuous variables were displayed as median with interquartile range (IQR) or means ± standard deviations, and compared using Mann-Whitney U test; Categorical data was shown as counts and percentages in each category, and compared by Chi-square test between group 1 and group 2. The boxplots were used to show distribution of laboratory testing results. Multivariate logistic regression was performed by forward stepwise (likelihood ratio) to explore risk factors for fibrotic changes in patients with COVID-19.

### RESULTS

#### General Characteristics of Patients

The last follow-up CT images were obtained on 56 days (median, IQR 51–63 days) after symptom onset and the median interval from onset to peak CT was longer in group 1 than in group 2 (23 vs. 18 days, p = 0.001) (Table 2).
Of 166 included patients (mean age, 57 ± 15 years, 42% [69/166] male), 76 patients (mean age, 63 ± 11 years, 49% [37/76] male) were designated as group 1 (with CT evidence of fibrotic pattern) and 90 patients (mean age, 52 ± 16 years, 36% [32/90] male) were designated as group 2 (without CT evidence of fibrotic pattern) (Table 2, Figure 1). According to Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (20), there were 127/166 (77%) severe or critical cases in our cohort (Table 2). Patients in group 1 were older and severer than in group 2 (both \( p < 0.001 \)). More patients in group 1 received non-invasive mechanical ventilation, glucocorticoids (methylprednisolone) and antibiotics than those in group 2 (all \( p < 0.05 \)) (Table 2).

### Laboratory Examinations

The peak laboratory data of patients during hospitalization was analyzed. Higher levels of leucocytes, neutrophils, eosinophils, monocytes counts, lactate dehydrogenase, erythrocyte sedimentation rate (ESR) and C-reactive protein were found in patients of group 1 when compared with group 2 (Table 3) (all \( p < 0.01 \)). As to cytokines testing, the interleukin-2 receptor (IL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor \( \alpha \) (TNF-\( \alpha \)) of patients in group 1 were significantly greater than that of patients in group 2 (all \( p < 0.05 \)) (Table 3). The boxplots of laboratory parameters were displayed in Figure 2.
Yang et al. Fibrotic Changes in COVID-19 Patients

FIGURE 3 | Series of follow-up CTs of a 40-year-old woman with COVID-19 who caught a fever on January 19, 2020 and was admitted at hospital on January 27, 2020. (A) Initial chest CT on January 22 (3 days after symptoms onset) showed sporadic GGO in bilateral lower lobes. (B–E) Two days later, consolidation appeared. Whereafter, the extent of GGO and consolidation enlarged, and reached its peak on February 11, and remained the peak level until February 20. (F, G) At the recovery stage, lesions were gradually absorbed. (H) On May 14 (116 days after symptoms onset), most consolidations were absorbed, while irregular interfaces and parenchymal bands were observed as evidence of fibrotic change (yellow arrow). COVID-19, coronavirus disease 2019; GGO, ground-glass opacity.

Image Findings on Peak and Last Follow-Up CTs

On last follow-up CTs, 76/166 (46%) patients showed CT evidences of fibrotic changes, manifesting as parenchymal bands (76% [58/76]), irregular interfaces (32% [24/76]) (Figure 3), traction bronchiectasis (38% [29/76]), lung distortion (25% [19/76]), and honeycombing (9% [7/76]). The fibrotic patterns principally showed peripheral distribution (89% [68/76]). The total scores of fibrotic changes presented as minimal or mild (1–10 points) in 84% (64/76) patients (Table 4). One patient was estimated as severe and no critical score were given. Besides, a total of 51 patients showed residual GGO or consolidation on the last follow-up CTs.

On peak CT, the main imaging features were GGO (154/166), consolidation (128/166) and reticulation/thickened interlobular septa (38/166) (Table 4, Figure 3). More patients presented with consolidation, reticulation/thickened interlobular septa and lung distortion in group 1 than did patients in group 2 (all p < 0.001) (Table 4). A higher total score on peak CT was found in group 1 (median, 16) than group 2 (median, 8) (p < 0.001). Lung distortion (a sign of fibrotic change) was found in 26 patients on their peak CTs, persisted in 13 patients and recovered in 13 patients on their last follow-up CTs (Figure 4).

Risk Factors of Fibrotic Change in Patients With COVID-19

According to multivariate logistic regression analysis, high total score on peak CT, eosinophils count, ESR and advancing age were related to fibrotic change on CT at early recovery stage in patients with COVID-19, with the odds ratios (ORs) of 1.156, 43.250, 1.024, and 1.048, respectively (all p < 0.05) (Table 5).

DISCUSSION

The investigation of fibrosis that may correlate with pulmonary functional changes is beneficial for better management of patients with COVID-19. However, relevant evidence has not been reported. In our study, 46% (76/166) patients presented with fibrotic changes on follow-up CT during early recovery phase (56 days after symptom onsets), and the extent of fibrotic changes in 84% (64/76) patients was minimal or mild. According to multivariate logistic regression, high total score on peak CT, peak eosinophils, ESR and advancing age were related to fibrotic changes depicted by CT in patients recovering from COVID-19.

Fibrotic patterns on CT occurred in less than half (46%, 76/166) of patients in this study, which is lower than that of patients with SARS (62%) (16) and higher than that of patients with MERS (32%) (17). In our cohort, 77% were severe or critical cases, therefore, this data may more reflect the proportion of fibrotic change in critically ill patients. Though many patients showed CT evidence of fibrotic change at recovery phase, the extent of fibrotic pattern was not large. We speculated those fibrotic changes may not put a great impact on the clinical symptom and life quality, however, this should be validated through pulmonary function tests.

The median interval from onset to peak CT was longer in group 1 than in group 2, which indicated that patients with evidence of fibrotic change may have a longer and more serious lung infections, which is similar to the findings of...
TABLE 4 | Radiographic findings on peak chest CT and features of fibrotic change on last follow-up CT in patients with COVID-19.

| Radiographic features on peak chest CT | Total patients (n = 166) | With CT evidence of fibrosis (group 1, n = 76) | Without CT evidence of fibrosis (group 2, n = 90) | P-value |
|---|---|---|---|---|
| GGO | 154/166 (93%) | 71/76 (93%) | 83/90 (92%) | 0.766 |
| Consolidation | 128/166 (77%) | 69/76 (91%) | 59/90 (66%) | <0.001 |
| Reticulation/thickened interlobular septa | 38/166 (23%) | 31/76 (41%) | 7/90 (8%) | <0.001 |
| Lung distortion | 26/166 (16%) | 23/76 (30%) | 3/90 (3%) | <0.001 |
| Nodular lesions | 6/166 (4%) | 3/76 (4%) | 3/90 (3%) | 0.837 |
| Distribution of lesions on peak CT | | | | |
| 1–4 lung lobes | 58/166 (35%) | 9/76 (12%) | 49/90 (54%) | <0.001 |
| 5 lung lobes | 108/166 (65%) | 67/76 (88%) | 41/90 (46%) | |
| Total scores on peak chest CT | 12 (6–17) | 16 (12–20) | 8 (4–12) | <0.001 |
| 0 (None) | 2/166 (1%) | 0/76 (0%) | 2/90 (2%)* | |
| 1–5 (Minimal) | 26/166 (16%) | 2/76 (3%) | 24/90 (27%) | <0.001 |
| 6–10 (Mild) | 47/166 (28%) | 11/76 (14%) | 36/90 (40%) | |
| 11–15 (Moderate) | 34/166 (20%) | 18/76 (24%) | 16/90 (18%) | |
| 16–20 (Severe) | 37/166 (22%) | 28/76 (37%) | 9/90 (10%) | |
| 21–25 (Critical) | 20/166 (12%) | 17/76 (22%) | 3/90 (3%) | |

| Features of fibrotic change on last follow-up CT | Total patients (n = 166) | With CT evidence of fibrosis (group 1, n = 76) | Without CT evidence of fibrosis (group 2, n = 90) | P-value |
|---|---|---|---|---|
| Parenchymal bands | 58/166 (35%) | 58/76 (76%) | | |
| Irregular interfaces | 24/166 (14%) | 24/76 (32%) | | |
| Traction bronchiectasis | 29/166 (17%) | 29/76 (38%) | | |
| Lung distortion | 19/166 (11%) | 19/76 (25%) | | |
| Honeycombing | 7/166 (4%) | 7/76 (9%) | | |
| Distribution of fibrotic change on last follow-up CT | | | | |
| Peripheral | 68/166 (41%) | 68/76 (89%) | | |
| Peribronchovascular | 5/166 (3%) | 5/76 (7%) | | |
| Random | 3/166 (2%) | 3/76 (4%) | | |
| Total scores of fibrotic pattern on last follow-up CT | | | | |
| 1–5 (Minimal) | 45/166 (27%) | 45/76 (59%) | | |
| 6–10 (Mild) | 19/166 (11%) | 19/76 (25%) | | |
| 11–15 (Moderate) | 11/166 (7%) | 11/76 (14%) | | |
| 16–20 (Severe) | 1/166 (1%) | 1/76 (1%) | | |
| 21–25 (Critical) | 0 (0%) | 0 (0%) | | |

Data are n (%) or median (IQR). COVID-19, coronavirus disease 2019; GGO, ground-glass opacity.

*The two patients presented with severe and persistent respiratory symptom, however, all CT images of them during hospitalization were negative. The CTs performed in the severest clinical conditions were defined as peak chest CTs of the two patients.

Previous study (25). In this study, fibrotic pattern depicted by CT in most patients (89%, 68/76) had peripheral distribution, which was consistent with the predominant distribution of GGO and consolidation and suggested the recovery process of inflammation. The lung distortion (a sign of fibrosis) showed in 16% (26/166) patients on peak CT with 50% (13/26) existing persistently to the last follow-up CT and 50% (13/26) resolving (Figure 4). The median interval between symptom onsets and peak CT was 20 days. These findings suggested that patients with COVID-19 may develop lung fibrotic signs at an early stage and early fibrosis may be, at least partly, reversible (26) (Figure 5). Besides fibrosis, bronchial dilation, as a radiographic sign, can also be seen in the setting of acute/subacute inflammation, coughing or barotrauma (27, 28), and can be reversible. This may partly explain some reversible cases in our study. By the end of this study, there were still many patients with GGO unresolved. Persistent GGO may represent residual inflammation that may resolve or evolve to fibrosis over time. Therefore, longer follow-up time was needed for observing fibrosis changes and its impact on respiratory symptoms.

Several risk factors of fibrotic change in patients with COVID-19 were identified. Larger lesions extent and higher total CT score on peak CT reflect severer lung injury and inflammation in patients. During persistent or recurrent injury and repair, fibrosis can develop more commonly (26). It is effective and convenient to evaluate disease and predict fibrotic change in patients with COVID-19 using dynamic CTs to better manage infected patients.
A higher level of eosinophils count in patients with evidence of fibrotic change was observed in our study. Previous studies reported eosinophils could produce essential pro-fibrotic cytokines or chemokines, such as transforming growth factor β1 (TGF-β1), platelet-derived growth factor (PDGF), IL-13 and chemokine (C-C motif) ligand 18 (CCL18) (25, 29, 30). Based on our results, eosinophils count was a risk factor for fibrotic change with a high ORs (43.250), which suggested eosinophils count might be used to predict the fibrotic change in patients with COVID-19. IL-2R, 6, 8, and TNF-α are important pro-inflammatory cytokines, which may promote non-specific immune response and cause pulmonary injury (9). The results of the relative higher IL-2R, 6, 8, and TNF-α levels in patients with CT evidence of fibrosis support the points that those cytokines play a vital role in the inflammatory response and driving fibrosis in injured tissues. However, much still need to be learned about the mechanism of fibrosis changes caused by this highly infectious disease.

Mechanical stress induces lung fibrosis, and epithelial-mesenchymal transition may play an important role in mediating the ventilator-induced lung fibrosis (31). In our cohort, the proportion of patients with non-invasive mechanical ventilation treatment in group 1 (with CT evidence of fibrotic change) (9%, 7/76) was higher than that of patients in group 2 (0/90) (p = 0.011). However, it is difficult to assess the impact of mechanical ventilation on fibrosis formation because patients who need ventilator treatment always have severe pulmonary inflammation.

There are some limitations in our study. First, selected bias may have been involved due to the retrospective nature. Second, there is no pathologic confirmation of fibrosis in patients of this study. Third, true traction bronchiectasis caused by fibrotic tissue is non-reversible. In our study, bronchial dilation on CT images was recorded as a radiographic sign of fibrosis, which may appear confusing because this sign can be seen in acute/subacute inflammation and may be reversible and does not necessarily correspond to underlying fibrosis. Therefore, longer follow-up time and comprehensive analysis by considering clinical symptoms, laboratory exams and dynamic changes on CTs are necessary when evaluating pulmonary fibrosis on CT images.
TABLE 5 | Significant risk factors for fibrotic change depicted by CT in patients with COVID-19.

|                      | B     | SE    | P-value | OR   | 95% CI for the OR |
|----------------------|-------|-------|---------|------|-------------------|
| Total score on peak chest CT | 0.145 | 0.048 | 0.003   | 1.156| 1.052–1.271       |
| Eosinophils          | 3.767 | 1.633 | 0.021   | 43.250| 1.760–1062.706    |
| Erythrocyte sedimentation rate | 0.024 | 0.010 | 0.015   | 1.024| 1.005–1.045       |
| Age                  | 0.047 | 0.019 | 0.014   | 1.048| 1.009–1.087       |

B, regression coefficient; SE, standard error; OR, odds ratio; CI, confidence intervals; COVID-19, coronavirus disease 2019.

Lastly, it is better to assess fibrosis changes after a longer follow-up period, because GGO did not completely resolve in some patients by the end of our study. Our results summarized the preliminary and overall follow-up CT findings in patients at the early recovery stage of this disease.

In conclusion, in our study, 46% patients (mainly severe or critical cases) with COVID-19 have CT evidences of fibrotic pattern during early recovery phase, while the extent of fibrotic change was not large. The advancing age, high total score on peak CT, peak eosinophils and ESR were associated with fibrotic change depicted by CT in patients recovering from COVID-19. An extended follow up by CT imaging and pulmonary function testing is necessary to fully assess fibrotic change in patients recovering from COVID-19.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional review board of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s), nor the minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

ZY and CC: study design, information collection, statistical analysis, and manuscript editing. All authors have read and approved the manuscript.

REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. doi: 10.1056/NEJMoA2001017
2. Dong D, Tang Z, Wang S, Hui D, Gong L, Yu Y, et al. The role of imaging in the detection and management of COVID-19: a review. IEEE Rev Biomed Eng. (2020). doi: 10.1109/RBME.2020.2990959. [Epub ahead of print].
3. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. J Thorac Imaging. (2020) 2:e200152. doi: 10.1148/ryct.2020200152
4. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a
single-centered, retrospective, observational study. *Lancet Respir Med.* (2020) 8:475–81. doi: 10.1016/S2213-2600(20)30079-5

5. World Health Organization. Available online at: https://covid19.who.int/ (accessed May 14, 2020).

6. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032

7. Li K, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. *Invest Radiol.* (2020) 55:327–31. doi: 10.1097/RLI.0000000000000672

8. Xu X, Yu C, Qi J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *Eur J Nucl Med Mol Imaging.* (2020) 47:1275–80. doi: 10.1007/s00259-020-04735-9

9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

10. Chen N, Zhou M, Dong X, Hu L, Han F, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7

11. Wang D, Hu B, Hu C, Zhu F, Li X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* (2020) 323:1061–9. doi: 10.1001/jama.2020.1585

12. Liu J, Chen T, Yang H, Cai Y, Yu Q, Chen J, et al. Clinical and radiological changes of hospitalised patients with COVID-19 pneumonia from disease onset to acute exacerbation: a multicentre paired cohort study. *Eur Radiol.* (2020) 30:5702–8. doi: 10.1007/s00330-020-06916-4

13. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. *Radiology.* (2020) 295:715–21. doi: 10.1148/radiol.2020200370

14. Dai H, Zhang X, Xia J, Zhang T, Shang Y, Huang R, et al. High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China. *Int J Infect Dis.* (2020) 95:106–12. doi: 10.1016/j.ijid.2020.04.003

15. Zhou S, Wang Y, Zha T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. *AJR Am J Roentgenol.* (2020) 214:1287–94.doi: 10.2214/AJR.20.22975

16. Antonio GE, Wong KT, Hui DS, Wu A, Lee N, Yuen EH, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. *Radiology.* (2003) 228:810–5. doi: 10.1148/ radiol.2283030726

17. Das KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Indian J Radiol Imaging.* (2017) 27:342–9. doi: 10.4103/ijri.IJRI_469_16

18. Sun P, Jie S, Liu Z, Ren J, Li K, Xi L. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. *J Med Virol.* (2020) 92:612–7. doi: 10.1002/jmv.25735

19. World Health Organization. *Clinical Management of COVID-19* (2020). Available online at: https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19 (accessed November 9, 2020)

20. General Office of National Health Committee. Notice on the Issuance of a Program for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infected Pneumonia (Trial Seventh Edition) (2020-03-03). Available online at: http://www.nhc.gov.cn/yzygj/s7653p/202003/ 46c9294a7dfe4ecf80dc715912eb7089.shtml (accessed March 3, 2020).

21. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet Infect Dis.* (2020) 20:559–64. doi: 10.1016/S1473-3099(20)30176-6

22. Hsu HH, Tzao C, Wu CP, Chang WC, Tsai CL, Tung HJ, et al. Correlation of high-resolution CT, symptoms, and pulmonary function in patients during recovery from severe acute respiratory syndrome. *Chest.* (2004) 126:149–58. doi: 10.1378/chest.126.1.149

23. Ooi GC, Khong PL, Muller NL, Yiu WC, Zhou LJ, Ho JC, et al. Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients. *Radiology.* (2004) 230:836–44. doi: 10.1148/radiol.2303030853

24. Zhang L, Zhang C, Dong S, Song Q, Chi F, Liu L, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. *BMC Pulm Med.* (2016) 16:137. doi: 10.1186/s12890-016-0300-7

25. Kolahan S, Fernandez IE, Eickelberg O, Hartl D. Immune mechanisms in pulmonary fibrosis. *Am J Respir Cell Mol Biol.* (2016) 55:309–22. doi: 10.1165/rcmb.2016-021TR

26. Horovitz JC, Thannickal VJ. Mechanisms for the Resolution of Organ Fibrosis. *Physiology (Bethesda).* (2019) 34:43–55. doi: 10.1152/physiol.00333.2018

27. Sartorius A, Lu Q, Vieira S, Tonnellier M, Lenaour G, Goldstein I, et al. Mechanical ventilation and lung infection in the genes of air-space enlargement. *Crit Care.* (2007) 11:R14. doi: 10.1186/cc5680

28. Milliron B, Henry TS, Veeraraghavan S, Little BP. Bronchiectasis: mechanisms and imaging clues of associated common and uncommon diseases. *Radiographics.* (2015) 35:1011–30. doi: 10.1148/rg.2015140214

29. Wynn TA. Integrating mechanisms of pulmonary fibrosis. *J Exp Med.* (2011) 208:1339–50. doi: 10.1084/jem.20110551

30. Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. *Am J Pathol.* (2006) 169:2117–26. doi: 10.2353/ajpath.2006.060617

31. Cabrera-Benitez NE, Parotto M, Post M, Han B, Spieth PM, Cheng WE, et al. Mechanical stress induces lung fibrosis by epithelial-mesenchymal transition. *Crit Care Med.* (2012) 40:510–7. doi: 10.1097/CCM.0b013e31822f09d7

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yang, Chen, Huang, Zhou, Hu, Xia and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.